Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2008-07-22
2008-07-22
Padmanabhan, Sreeni (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S178000, C424S145100
Reexamination Certificate
active
07402578
ABSTRACT:
This invention generally pertains to the field of psychiatry. In particular, this invention pertains to the discovery that agents capable of inhibiting the binding of cortisol to its receptors can be used in methods for preventing or reversing cognitive deterioration in adults with Down's syndrome. Mifepristone, a potent specific glucocorticoid receptor antagonist, can be used in these methods. The invention also provides a kit for preventing or reversing cognitive deterioration in a DS patient including a glucocorticoid receptor antagonist and instructional material teaching the indications, dosage and schedule of administration of the glucocorticoid receptor antagonist.
REFERENCES:
patent: 6150349 (2000-11-01), Schatzberg et al.
patent: WO 99/17779 (1999-04-01), None
patent: WO 9959596 (1999-11-01), None
patent: WO 01/37840 (2001-05-01), None
Sekijima et al. European Neurology, (1998) 39 (4) 234-7.
Beers, M., The Merck Manual of Diagnosis and Therapy (17th Ed) (1999), p. 2233-2235.
Aylward, Elizabeth H. et al.; “MRI Volumes fo the Hippocampus and Amygdala in Adults with Down's Syndrome With and Without Dementia”;Am. J. Psychiatry; Apr. 1999; pp. 564-568; vol. 156, No. 4.
Burt, Diana B. et al.; “Dementia in Adults With Down Syndrome: Diagnostic Challenges”;American Journal on Mental Retardation; 1998; pp. 130-145; vol. 103, No. 2; American Association on Mental Retardation.
Geldmacher, Davis S. et al.; “Treatment of Functional Decline in Adults with Down Syndrome Using Selective Serotonin-Reuptake Inhibitor Drugs”;J. Geriatr. Psychiatry Neurol.; 1997; pp. 99-104; vol. 10.
Iannello, R. C. et al.; “Oxidative stress and neural dysfunction in Down Syndrome”;J. Neural Transm.; 1999; pp. 257-267; vol. 57 [Suppl]; Springer-Verlag.
Johannsen, Peter et al.; “The Prevalence of Dementia in Down Syndrome”;Dementia; 1996; pp. 221-225; vol. 7; S. Karger AG; Basel.
Kesslak, J. P. et al.; “Magnetic resonance imaging analysis of age-related changes in the brains of individuals with Down's Syndrome”;Neurology; Jun. 1994; pp. 1039-1045; vol. 44.
Murdoch, J. C. et al.; “Hypothalamic-pituitary-adrenocortical function in adults with Down's Syndrome”;J. Ment. Defic. Res.; 1979; pp. 157-162; vol. 23.
EMBASE Database on ACS; Accession No. 1999057454; Oitzl, M. S. et al.; “Continuous blockade of brain glucocorticoid receptors facilitates spatial learning and memory in rats”;European Journal of Neuroscience; 1998; pp. 3759-3766; vol. 10, No. 12; Abstract.
Tuor, U.I. and M.R. Del Bigio; “Protection against hypoxic-ischemic damage with corticosterone and dexamethasone; inhibition of effect by a glucocorticoid antagonist, RU38486”;Brain Research; 1996; pp. 258-262; vol. 743; Elsevier Science B.V.
Corcept Therapeutics, Inc.
Padmanabhan Sreeni
Townsend and Townsend / and Crew LLP
Williams L
LandOfFree
Methods for inhibiting cognitive deterioration in adults... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for inhibiting cognitive deterioration in adults..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for inhibiting cognitive deterioration in adults... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2805651